Commonwealth Equity Services’s Maravai LifeSciences MRVI Stock Holding History

Commonwealth Equity Services’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,166	Closed	-$216K	–	3768
2021 Q4	$216K	Hold	5,166	–	–	﹤0.01%	3239
2021 Q3	$253K	Buy	+5,166	New	+$252K	﹤0.01%	3073

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Commonwealth Equity Services's MRVI Position: Q1 2022 in Review

Commonwealth Equity Services sold out of Maravai LifeSciences (MRVI) in Q1 2022, closing a stake of 5,166 shares — an estimated $216K sold.

Commonwealth Equity Services first reported a position in MRVI in Q3 2021 and held it in 2 quarters. The position peaked at $253K in Q3 2021. 235 funds tracked by Wall St. Rank hold MRVI as of Q1 2022.

Commonwealth Equity Services reported no remaining Maravai LifeSciences position as of Q1 2022 after selling out during the quarter.
Commonwealth Equity Services sold 5,166 Maravai LifeSciences shares in Q1 2022, an estimated $216K.
Commonwealth Equity Services first reported a position in Maravai LifeSciences in Q3 2021 and held it in 2 quarters.
Commonwealth Equity Services's Maravai LifeSciences position peaked at $253K in Q3 2021.
235 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2022.

Based on Commonwealth Equity Services's 13F filing for Q1 2022, filed 4 May 2022.